# A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

> **NCT01316822** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 26 (actual)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** ARRY-382, cFMS inhibitor; oral

## Key facts

- **NCT ID:** NCT01316822
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316822, "A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01316822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*